Theravance Biopharma Inc Stock News

DUBLIN , Oct. 24, 2024 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) will report its third quarter 2024 financial results and provide a business update after market close on Tuesday, November 12, 2024. An accompanying conference call and simultaneous webcast will be hosted at 5:00 pm EST (2:00 pm PST/10:00 pm GMT) that day.

DUBLIN , Oct. 18, 2024 /PRNewswire/ -- Theravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (NASDAQ: TBPH) today announced the publication of a sub-study of the pivotal 12-week, randomized, registrational revefenacin Phase 3 trials (Trials 0126 [NCT02459080] and 0127 [NCT02512510]) for YUPELRI, the first and only FDA approved once-daily nebulized long-acting muscarinic antagonis...

Enigmatic investing legend Seth Klarman runs the Boston-based Baupost Group hedge fund that has around $27 billion in assets under management.

DUBLIN , Aug. 27, 2024 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) will participate in a Fireside Chat at the H.C. Wainwright 26th Annual Global Investment Conference in New York City on Tuesday, September 10 at 10:00 am ET (7:00 am PT/3:00 pm IST) and will be hosting in-person meetings with the investment community at the conference.

Theravance Biopharma, Inc. (NASDAQ:TBPH ) Q2 2024 Earnings Conference Call August 5, 2024 5:00 PM ET Company Participants Rick Winningham - Chief Executive Officer Aine Miller - Head, Development Rhonda Farnum - Chief Business Officer Aziz Sawaf - Chief Financial Officer Conference Call Participants Douglas Tsao - H.C. Wainright David Risinger - Leerink Partners Ernie Rodriguez - TD Cowen Liisa...

Q2 2024 YUPELRI® (revefenacin) net sales of $54.5 million, recognized by Viatris, decreased 1% from Q2 2023 1 Viatris collaboration revenue of $14.3 million, increased 4% versus Q2 2023 Partner Viatris submitted YUPELRI NDA in China; $7.5 million milestone if approved Now expecting last patient into the open label portion of CYPRESS in mid-2025, top line data anticipated approximately 6 months ...

DUBLIN , July 25, 2024 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) will participate in a fireside chat at the BTIG Virtual Biotechnology Conference on Tuesday, August 6 at 12:00 pm ET (9:00 am PT/5:00 pm IST). Members of Theravance Biopharma senior management will also be hosting one-on-one meetings at the conference.

DUBLIN , July 22, 2024 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) will report its second quarter 2024 financial results and provide a business update after market close on Monday, August 5, 2024. An accompanying conference call and simultaneous webcast will be hosted at 5:00 pm ET (2:00 pm PT/10:00 pm IST) that day.